L-Carnitine and Reduced Mortality Risk

• Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study.

  • 2022-08-23
  • RCT · n = 75
  • Pharmacological reports : PR 74(6)
  • • Seyed Saman Talebi
    • Mehran Ghasemi
    • Maryam Etminani-Esfahani
    • Younes Mohammadi
    • Rasool Haddadi

  • PubMed: 35997951
  • DOI: 10.1007/s43440-022-00402-y

  9 Insights on

  • Reduced Mortality Risk

  • High evidence
  • Clinical

  six patients (14%) in the control group died due to the complications of COVID-19, while all patients in the intervention group survived.

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes

  Dose

  3000 mg oral L-carnitine daily in three divided doses for five days

• Impact of L-carnitine supplementation on post-transplant outcomes in liver transplant candidates with sarcopenia: A randomized controlled open-label trial.

  • 2025-12
  • RCT · n = 18
  • Clinical nutrition ESPEN 70
  • • Marwa Abd El-Razek Salama
    • Elham Ahmed Hassan
    • Nahed A Makhlouf

  • PubMed: 40962224
  • DOI: 10.1016/j.clnesp.2025.09.008

  2 Insights on

  • Reduced Mortality Risk

  • High evidence
  • Clinical

  Mortality was significantly lower in the L-carnitine group (16.7 % vs. 55.6 %; P = 0.003)

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes